Top

International Journal of Colorectal Disease

Published in:

01-05-2012 | Original Article

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases

Authors: Hannes P. Neeff, Oliver Drognitz, Andrea Klock, Gerald Illerhaus, Oliver G. Opitz, Ulrich T. Hopt, Frank Makowiec

Published in: International Journal of Colorectal Disease | Issue 5/2012

Abstract

Purpose

The impact of chemotherapy (CTx) on morbidity after liver resection for colorectal metastases (CRC-LM) has been increasingly investigated during recent years. Biologic agents like bevacizumab (BEV) or cetuximab (CET) are now added as “targeted therapy” (TT), also in neoadjuvant settings. Initial series could demonstrate the safety of those regimens in liver resection but data are still scarce. We evaluated the impact of CTx with BEV or CET (CTx + TT) on perioperative morbidity and mortality.

Methods

Two hundred thirty-seven patients who underwent liver resections for CRC-LM after chemotherapy before surgery since 1999 were included. One hundred eighty-five patients (78%) had preoperative CTx regimen without biologic agents (fluoropyrimidine-, oxaliplatin-, or irinotecan-based) and 52 (22%) had CTx + TT (39 BEV, 11 CET, 2 CET/BEV). After preoperative CTx + TT, a time interval of at least 4–6 weeks and a residual liver volume of >35% before surgery were required.

Results

Hemihepatectomy or more was performed in about half of the patients. The median amount of intraoperatively transfused blood was 0 ml in both groups (p = 0.34). Overall mortality was 1.7% and slightly elevated in patients with CTx + TT (3.8% vs. 1.1%, p = 0.17). Any complication occurred in (CTx + TT vs. CTx) 52% and 46%, respectively (p = 0.47). The rates of liver failure (9.6% vs. 9.7%, p = 0.98), infectious complications such as wound infection (19% vs. 16%, p = 0.62) and abdominal abscess (8% vs. 6.5%, p = 0.71), as well as the rate of relaparotomies (11.5% vs. 7.0%, p = 0.29) showed no significant differences between the groups with TT or without. In multivariate analyses, neither type nor duration of CTx nor the time interval between CTx and surgery showed any influence on complication rates.

Conclusions

Our data confirm the safety of targeted therapy before liver resection for CRC-LM. This effect may in part be due to our treatment policy (time interval to resection and residual liver volume) after intensive preoperative CTx.

Boyle P, Leon ME (2002) Epidemiology of colorectal cancer. Br Med Bull 64:1–25PubMedCrossRef

Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:191–197. doi:10.1055/s-0029-1242458 PubMedCrossRef

Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212–2221. doi:10.1016/j.ejca.2006.04.012 PubMedCrossRef

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCrossRef

Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825PubMedCrossRef

Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. AnnSurg 241:715–22, discussionPubMedCrossRef

Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S, Wei AC (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468–475PubMedCrossRef

Neeff H, Hörth W, Makowiec F, Fischer E, Imdahl A, Hopt UT, Passlick B (2009) Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg 13:1813–1820. doi:10.1007/s11605-009-0960-1 PubMedCrossRef

Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(2):ii13–ii16PubMedCrossRef

10.

Pawlik TM, Schulick RD, Choti MA (2008) Expanding criteria for resectability of colorectal liver metastases. Oncologist 13:51–64. doi:10.1634/theoncologist.2007-0142 PubMedCrossRef

11.

Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P (2002) Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95:2283–2292. doi:10.1002/cncr.10973 PubMedCrossRef

12.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–57, discussion 657–8PubMedCrossRef

13.

Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B et al (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866–4875. doi:10.1200/JCO.2005.07.113 PubMedCrossRef

14.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676. doi:10.1200/JCO.2006.09.0928 PubMedCrossRef

15.

Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–20, discussion 520–2PubMedCrossRef

16.

Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420–425. doi:10.1097/SLA.0b013e31819a0486 PubMedCrossRef

17.

Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Ijzermans J, Hubert C et al (2010) Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252:774–787. doi:10.1097/SLA.0b013e3181fcf3e3 PubMedCrossRef

18.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi:10.1056/NEJMoa032691 PubMedCrossRef

19.

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048. doi:10.1056/NEJMoa071834 PubMedCrossRef

20.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765. doi:10.1056/NEJMoa0804385 PubMedCrossRef

21.

Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466PubMedCrossRef

22.

Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072. doi:10.1200/JCO.2005.05.3074 PubMedCrossRef

23.

Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860–868. doi:10.1007/s11605-007-0149-4 PubMedCrossRef

24.

Makowiec F, Möhrle S, Neeff H, Drognitz O, Illerhaus G, Opitz OG, Hopt UT, zur Hausen A (2011) Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg 15(11):153–64. doi:10.1007/s11605-010-1368-7 PubMedCrossRef

25.

Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788–1795. doi:10.1038/sj.bjc.6603813 PubMedCrossRef

26.

Tarnawski AS, Jones MK (1998) The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol 27(Suppl 1):S12–S20PubMedCrossRef

27.

Ito H, Are C, Gonen M, D'Angelica M, Dematteo RP, Kemeny NE, Fong Y, Blumgart LH, Jarnagin WR (2008) Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247:994–1002. doi:10.1097/SLA.0b013e31816c405f PubMedCrossRef

28.

Schepers A, Mieog S, van de Burg BB, van Schaik J, Liefers GJ, Marang-van de Mheen PJ (2010) Impact of complications after surgery for colorectal liver metastasis on patient survival. J Surg Res 164:e91–e97. doi:10.1016/j.jss.2010.07.022 PubMedCrossRef

29.

Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 236:397–406. doi:10.1097/01.SLA.0000029003.66466.B3 PubMedCrossRef

30.

Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38–46PubMedCrossRef

31.

Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli M, Del Gaudio M, Pinna AD (2009) Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg 249:995–1002. doi:10.1097/SLA.0b013e3181a63c74 PubMedCrossRef

32.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572. doi:10.1056/NEJMoa0808268 PubMedCrossRef

33.

Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853. doi:10.1016/j.jamcollsurg.2005.01.024 PubMedCrossRef

34.

Fong Y, Bentrem DJ (2006) CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 243:8–9PubMedCrossRef

35.

Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR (2003) Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7:1034–1044PubMedCrossRef

36.

Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P, Yamazaki S, Hasegawa H, Ozaki H (1990) Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107:521–527PubMed

37.

Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H (2000) Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232:777–785PubMedCrossRef

38.

Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173–180. doi:10.1002/jso.20301 PubMedCrossRef

39.

D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case–control study. Ann Surg Oncol 14:759–765. doi:10.1245/s10434-006-9074-0 PubMedCrossRef

40.

Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254–5260. doi:10.1200/JCO.2008.17.7857 PubMedCrossRef

41.

Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106. doi:10.1016/j.jamcollsurg.2007.06.290 PubMedCrossRef

42.

Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T (2010) Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg 252:124–130. doi:10.1097/SLA.0b013e3181deb67f PubMedCrossRef

43.

Pessaux P, Panaro F, Casnedi S, Zeca I, Marzano E, Bachellier P, Jaeck D, Chenard MP (2010) Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case–control study. Eur J Surg Oncol 36:575–582. doi:10.1016/j.ejso.2010.04.010 PubMedCrossRef

44.

Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, Mittal V, Kobayashi H et al (2010) Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468:310–315. doi:10.1038/nature09493 PubMedCrossRef

45.

van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malagó M, Jalan R, Saner FH (2008) Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 28:767–780. doi:10.1111/j.1478-3231.2008.01777.x PubMedCrossRef

46.

Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850PubMed

47.

Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1–7PubMedCrossRef

48.

Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553–1559. doi:10.1245/s10434-009-0447-z PubMedCrossRef

49.

Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15:2765–2772. doi:10.1245/s10434-008-0035-7 PubMedCrossRef

50.

Peeters M, Price T, Van Laethem JL (2009) Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14:29–39. doi:10.1634/theoncologist.2008-0167 PubMedCrossRef

51.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345. doi:10.1056/NEJMoa033025 PubMedCrossRef

52.

Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010–1017. doi:10.1634/theoncologist.11-9-1010 PubMedCrossRef

53.

Fakih M, Vincent M (2010) Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 17(Suppl 1):S18–S30PubMed

54.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343:905–914. doi:10.1056/NEJM200009283431302 CrossRef

55.

Nagino M, Kanai M, Morioka A, Yamamoto H, Kawabata Y, Hayakawa N, Nimura Y (2000) Portal and arterial embolization before extensive liver resection in patients with markedly poor functional reserve. J Vasc Interv Radiol 11:1063–1068PubMedCrossRef

56.

Gruttadauria S, Luca A, Mandala' L, Miraglia R, Gridelli B (2006) Sequential preoperative ipsilateral portal and arterial embolization in patients with colorectal liver metastases. World J Surg 30:576–578. doi:10.1007/s00268-005-0423-0 PubMedCrossRef

57.

Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F et al (2010) Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 11:845–852. doi:10.1016/S1470-2045(10)70175-3 PubMedCrossRef

Title: Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases
Authors: Hannes P. Neeff
Oliver Drognitz
Andrea Klock
Gerald Illerhaus
Oliver G. Opitz
Ulrich T. Hopt
Frank Makowiec
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 5/2012
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-011-1360-z

At a glance: The STEP trials

Springer Medicine

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer

Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy?

The effect of oral tolerance on the roles of small intestinal intraepithelial lymphocytes in murine colitis induced by dextran sodium sulfate

Endometrioid adenocarcinoma arising from colonic endometriosis in a Lynch syndrome patient

Analysis of the seventh edition of American Joint Committee on colon cancer staging

The JAK2 variant rs10758669 in Crohn’s disease: altering the intestinal barrier as one mechanism of action